Editorial - Avoiding Unethical Helicobacter pylori Clinical Trials: Susceptibility-Based Studies and Probiotics as Adjuvants

Helicobacter

Volumn 20, Issue 5, 2015, Pages 321-325

  Graham, David Y ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Equipoise; Ethics; Helicobacter pylori; Probiotic; Treatment

Indexed keywords

CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; PROBIOTIC AGENT; PHARMACEUTICAL VEHICLES AND ADDITIVES;

ADJUVANT THERAPY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; DRUG EFFICACY; EDITORIAL; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MEDICAL EXPERT; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC); ETHICS;

ADJUVANTS, PHARMACEUTIC; CLINICAL TRIALS AS TOPIC; HELICOBACTER PYLORI; PROBIOTICS;

EID: 84941738305     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/hel.12244     Document Type: Editorial

References (29)

1. Laxminarayan R, Bhutta Z, Duse A, Jenkins P, O'Brien T, Okeke IN, Pablo-Mendez A, Klugman KP. Drug resistance. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P, eds. Disease control priorities in developing countries, 2nd edn. Washington: World Bank, 2006;1031-52.
2. Graham DY. Helicobacter pylori Update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology 2015;148:719-31.
3. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014;12:177-86.
4. Graham DY. Helicobacter pylori eradication therapy research: ethical issues and description of results. Clin Gastroenterol Hepatol 2010;8:1032-6.
5. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med 1987;317:141-5.
6. Tremaine WJ. Equipoise, H. pylori, and Musketeers - choosing an appropriate standard clinical care regimen. Helicobacter 2008;13:79-80.
7. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA 2000;283:2701-11.
8. Miller FG, Brody H. A critique of clinical equipoise. Therapeutic misconception in the ethics of clinical trials. Hastings Cent Rep 2003;33:19-28.
9. Zullo A, Vaira D, Vakil N, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003;17:719-26.
10. Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013;347:f4587.
11. Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011;378:507-14.
12. Wang ZH, Gao QY, Fang JY. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol 2013;47:25-32.
13. Molina-Infante J, Gisbert JP. Probiotics for Helicobacter pylori eradication therapy: not ready for prime time. Rev Esp Enferm Dig 2013;105:441-4.
14. Zheng X, Lyu L, Mei Z. Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a meta-analysis. Rev Esp Enferm Dig 2013;105:445-53.
15. Dang Y, Reinhardt JD, Zhou X, Zhang G. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. PLoS ONE 2014;9:e111030.
16. Fischbach LA, van ZS, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 2004;20:1071-82.
17. Graham DY, Karttunen TJ, Genta RM. The evaluation of treatment of H. pylori infections: strategies for the design of clinical trials. Endoscop Digest 1994;6:991-1006.
18. Attumi TA, Graham DY. High-dose extended-release lansoprazole (dexlansoprazole) and amoxicillin dual therapy for Helicobacter pylori infections. Helicobacter 2014;19:319-22.
19. Bontems P, Kalach N, Oderda G, Salame A, Muyshont L, Miendje DY, Raymond J, Cadranel S, Scaillon M. Sequential therapy versus tailored triple therapies for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr 2011;53:646-50.
20. Furuta T, Shirai N, Kodaira M, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther 2007;81:521-8.
21. Kawai T, Yamagishi T, Yagi K, et al. Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities. J Gastroenterol Hepatol 2008;23(Suppl 2):S171-4.
22. Lee HJ, Kim JI, Cheung DY, et al. Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance. J Infect Dis 2013;208:1123-30.
23. Martos M, Bujanda L, Salicio Y, Sarasqueta C, Ibarra B, Mendarte U, Fernandez-Reyes M, Cosme A. Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance regions. Eur J Gastroenterol Hepatol 2014;26:1380-4.
24. Neri M, Milano A, Laterza F, Di Bonaventura G, Piccolomini R, Caldarella MP, Balatsinou C, Lapenna D, Cuccurullo F. Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments. Aliment Pharmacol Ther 2003;18:821-7.
25. Park CS, Lee SM, Park CH, et al. Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based Triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance. Am J Gastroenterol 2014;109:1595-602.
26. Romano M, Marmo R, Cuomo A, De ST, Mucherino C, Iovene MR, Montella F, Tufano MA, Del Vecchio BC, Nardone G. Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori. Clin Gastroenterol Hepatol 2003;1:273-8.
27. Toracchio S, Cellini L, Di CE, Cappello G, Malatesta MG, Ferri A, Ciccaglione AF, Grossi L, Marzio L. Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. Aliment Pharmacol Ther 2000;14:1639-43.
28. Cammarota G, Ianiro G, Bibbo S, Di Rienzo TA, Masucci L, Sanguinetti M, Gasbarrini A. Culture-guided treatment approach for Helicobacter pylori infection: review of the literature. World J Gastroenterol 2014;20:5205-11.
29. Wang G, Zhao Q, Li S. Study of drug sensitivity test in Helicobacter pylori eradication therapy. J Clin Intern Med 2008;25:1639-43.